Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
Font Down Font Up

 
Varian Reports Decline In Q4 Profit; EPS Misses Estimate - Update
11/4/2009 8:52 PM  ET

RELATED NEWS
Varian, Inc. Q4 Profit Declines - Quick Facts
Varian Reveals Stockholder Approval Of Merger Agreement With Agilent Technologies - Quick Facts
Varian Announces Stockholder Approval Of Merger Agreement With Agilent Tech. - Quick Facts
TOP MARKET NEWS
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary
Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary
New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening
Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary
(RTTNews) -  Wednesday, Varian, Inc. (VARI: News ) reported a decline in profit for the fourth quarter, as the global economic slowdown and customers' uncertainty and other disruptions related to the pendency of the acquisition by Agilent hit sales.

Net income for the fourth quarter was $1.9 million or earnings of $0.07 per share, compared with $20.3 million or earnings of $0.69 per share in the same period last year. Adjusted net income for the period was $11.5 million or $0.40 per share, compared to $23.0 million or $0.78 per share in the same quarter last year.

On average, six analysts polled by Thomson Reuters expected the company to earn $0.68 per share. Analysts' estimates typically exclude special items.

Sales for the quarter declined to $196.45 million from $282.47 million in the prior year period. Six Wall Street analysts estimated revenues of 225.62 million for the quarter.

Scientific Instruments revenues for the fourth quarter of 2009 declined by 30.3% to $164.7 million, from the fourth quarter of the prior year, while Vacuum Technologies revenues declined by 31.0% to $31.7 million in the fourth quarter of 2009.

According to Varian, revenues in the fourth quarter of fiscal year 2009 were lower than the prior-year quarter, primarily due to the global economic downturn as well as specific items impacting the comparability of the fourth quarter of fiscal year 2009 with the comparable period year-ago. In addition, revenues were negatively impacted by customers' uncertainty and other disruptions related to the announcement and pendency of the acquisition by Agilent.
Cost of sales for the period declined to $113.26 million from $156.37 million during the period and total operating expenses declined to $78.09 million from $93.23 million during the prior year quarter.

The company said that as announced on July 26 it entered into an Agreement and Plan of Merger with Agilent, pursuant to which the company will, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, be acquired by Agilent for $52.00 per share in cash. Varian added that at a special meeting held on October 5, the company's stockholders approved the Merger Agreement and that the transaction remains subject to regulatory approvals and other closing conditions.

For the fiscal year, net earnings declined to $38.62 million or earnings of $1.34 per share, compared with $65.11 million or earnings of $2.17 per share in the year-ago period. Year-to-date net earnings on an adjusted basis declined to $58.04 million or earnings of $2.01 per share, compared with $78.68 million or earnings of $2.62 per share in the prior year period. Full-year sales declined to $806.74 million from $1.012 billion in the year-ago period.

To receive FREE breaking news email alerts for Varian Inc. and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
  Trading Center
 

More Breaking News-US

129  Retired US Official, Wife Admit Spying For Cuba
128  Italian Police Arrest Two Pakistanis Linked To Mumbai Attacks
127  Indian Appointed To Key IMF Post
126  FDA Approves Bristol-Myers' Abilify To Treat Irritabilty In Pediatric Patients With Autistic Disorder - Update
125  EU Extends Review Deadline For Oracle's Proposed Takeover Of Sun Micro - Update
124  Pfizer's Geodon Approved As Adjunctive For Bipolar Disorder - Update
123  CF Nominees Enter Terra's Board - Update
122  Archipelago Learning Prices IPO Within Expected Range; Stock Soars - Update
121  Brown University And IBM Launch Multimillion-Dollar Supercomputer - Update
120  GLG Life Tech Starts Trading On Nasdaq; Shares Down 13.7% - Update
119  Global Defense Technology Prices IPO At $13/Share, Below Prior Estimate - Update
118  Dendreon Gets FDA Acceptance For Prostrate Cancer Drug Application - Update
117  Covidien's Pain Drug NDA Review Extended By FDA - Update
116  Inovio's Pre-clinincal Study Of Universal Flu Vaccines Reports Protective Response Against Multiple Influenza Strains; Stock Up - Update
115  Cloud Peak Energy Prices IPO At $15/shr - Update
  

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS